Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

Neuropsychobiology

Volumn 49, Issue 4, 2004, Pages 167-173

  Liou, Ying Jay ^a,d   Wang, Ying Chieh ^a,b   Bai, Ya Mei ^a,e   Lin, Chao Cheng ^a   Yu, Shun Chieh ^c   Liao, Ding Lieh ^f   Lin, Ming Wei ^d,g   Chen, Jen Yeu ^a   Lai, I Ching ^a,h  

^a YULI VETERANS HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c Yuli Hospital   (Taiwan)

^d Georgetown Univ School of Medicine   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f Pali Psychiatric Hospital   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h NONE   (Taiwan)

Author keywords

Association study; CYP2D6; Cyp2d6*10; Polymorphism; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOCHROME P450 2D6 10 C188T GENE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MENTAL PATIENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SEX DIFFERENCE; TARDIVE DYSKINESIA;

ADULT; ALLELES; AMINO ACID SUBSTITUTION; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYSTEINE; CYTOCHROME P-450 CYP2D6; DYSKINESIA, DRUG-INDUCED; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA; SEX FACTORS; STATISTICS, NONPARAMETRIC; THREONINE;

EID: 2342562985     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077360     Document Type: Article

References (29)

1. Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, Schooler NR, Mukherjee S, Rotrosen J, Rubinstein M: The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42.
2. Casey DE: Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999;35:S61-S66.
3. Casey DE: Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-120.
4. Casey DE: Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10(suppl 3):105-114.
5. Tugg LA, Desai D, Prendergast P, Remington G, Reed K, Zipursky RB: Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. Schizophr Res 1997;25:71-78.
6. Bertilsson L, Dahl ML, Ekqvist B, Llerena A: Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation. Psychopharmacol Ser 1993;10:230-237.
7. Jerling M, Dahl ML, Aberg-Wistedt A, Liljenberg B, Landell NE, Bertilsson L, Sjoqvist F: The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59:423-428.
8. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
9. Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, Waye MM: Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 2000;46:18-23.
10. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR: Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997;170:23-26.
11. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM: Non-functional CYP2D6 alleles and risk for neurolepticinduced movement disorders in schizophrenic patients. Psychopharmacology 1997;131:174-179.
12. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S: Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998;32:101-106.
13. Ellingrod VL, Schultz SK, Arndt S: Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy 2002;22:1416-1419.
14. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-397.
15. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML: Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-418.
16. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, Abe K: Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998;32:107-113.
17. Lam LC, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VK, Kwong SL, Lau BS, Kwong PP, Waye MM, Chiu HF: Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 2001;34:238-241.
18. Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G: Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 2003;13:163-168.
19. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486-487.
20. Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L: Cigarette smoking is associated with abnormal involuntary movements in the general male population - A study of men born in 1933. Biol Psychiatry 1997;41:717-723.
21. Nikoloff D, Shim JC, Fairchild M, Patten N, Fijal BA, Koch WH, MacPherson A, Flockhart D, Yoon YR, Yoon JS, Kim YH, Shin JG: Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2002;2:400-407.
22. Arthur H, Dahl ML, Siwers B, Sjoqvist F: Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995;15:211-216.
23. Gorrod JW, Fang J: On the metabolism of haloperidol. Xenobiotica 1993;23:495-508.
24. Oida T, Terauchi Y, Yoshida K, Kagemoto A, Sekine Y: Use of antisera in the isolation of human specific conjugates of haloperidol. Xenobiotica 1989;19:781-793.
25. Subramanyam B, Rollema H, Woolf T, Castagnoli N Jr: Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 1990; 166:238-244.
26. Pape BE: Isolation and identification of a metabolite of haloperidol. J Anal Toxicol 1981;5:113-117.
27. Inaba T, Kovacs J: Haloperidol reductase in human and guinea pig livers. Drug Metab Dispos 1989;17:330-333.
28. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR: Effects of haloperidol metabolites on neurotransmitter uptake and release: Possible role in neurotoxicity and tardive dyskinesia. Brain Res 1998;788:215-222.
29. Someya T, Shimoda K, Suzuki Y, Sato S, Kawashima Y, Hirokane G, Morita S, Yokono A, Takahashi S: Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology 2003;28:1501-1505.